Production (Stage)
Cadrenal Therapeutics, Inc.
CVKD
$13.69
-$0.014-0.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -131.19% | -265.99% | -132.30% | -138.58% | 67.85% |
| Total Depreciation and Amortization | 816.67% | -33.33% | -33.33% | -16.67% | 200.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 237.52% | 640.25% | 95.76% | 14.95% | -96.17% |
| Change in Net Operating Assets | -303.72% | 372.10% | -136.76% | 1,609.95% | 32.16% |
| Cash from Operations | -153.15% | -157.88% | -250.62% | -92.28% | -29.98% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 685,066.67% | -- | -76.52% | -- | -99.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 656,600.00% | 59,710.40% | -76.52% | -- | -99.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -46.07% | 899.83% | -111.45% | -91.49% | -145.95% |